Polycythemia Vera Presenting as Hemorrhagic Stroke

Krishnan Balagopal1 Aju Mathew2 Ansa Grace Koshy1 Jerin Peter Jacob1

1Department of Neurology, MOSC Medical College, Kolenchery, Kochi, Kerala, India
2Department of Hemato-Oncology, MOSC Medical College, Kolenchery, Kochi, Kerala, India

Address for correspondence Krishnan Balagopal, DM, Department of Neurology, MOSC Medical College, Medical College Road, PO kolencherrym, Kochi, Kerala 682311, India (e-mail: krishnan.balagopal@gmail.com).

Introduction

Polycythemia vera (PV) is a myeloproliferative disease characterized by clonal proliferation of hematopoietic stem cells, leading to abnormal increases in circulating red blood cells, white blood cells, and platelets, resulting in an increase in blood viscosity and reduction in blood flow velocity. These disorders of hemorheology are contributing factors for thrombosis, resulting in cerebral infarction. In some situations, the condition is associated with cerebral hemorrhage due to dysfunction in platelet aggregation and the prolongation of activated partial prothrombin time. Stroke may be the first presenting symptom of PV in 15% or more of those affected by the disease. Here, we present a case of a 65-year-old patient who presented with bilateral hemorrhagic infarcts.

Case Report

A 65-year-old woman with a history of diabetes and hypertension presented to the emergency department with an episode of generalized seizures, followed by weakness of left upper and lower extremities and altered sensorium. On examination, the patient was noted to be in the postictal state with left hemiparesis. Her blood pressure was 180/100 mm Hg. Imaging studies showed areas of infarction in bilateral parieto-occipital, right thalamic, right basal ganglia, and frontal white matter (Figs 1–5). Hemorrhagic transformation was seen in bilateral parieto-occipital regions. Magnetic resonance angiography (MRA) of the brain showed hypoplastic right vertebral artery. On laboratory evaluation, she was noted to have a hemoglobin level of 16.1 g/dL associated with elevated total white blood count of 49,390/mm3 and platelet count of 8.35 lakhs/mm3. We considered the possibility of a myeloproliferative neoplasm. Genetic work-up revealed a JAK2 V617F mutation, which is characteristically seen in patients with PV. She was started on antiplatelet agents. We also performed therapeutic phlebotomy to reduce the hemoglobin to a goal of less than 14.5 g/dL. Subsequently, both her sensorium and motor power improved with physiotherapy. To keep her platelet count to a goal of less than 5 lakhs/mm3, we also started her on hydroxyurea.
Discussion

PV is a rare cause of both cerebral thrombosis and hemorrhage. The etiology of PV is attributed to a gain of function mutation of the JAK2 domain (Janus Activated Kinase (JAK)2 V617F mutation) found in more than 95% of patients. Chemotherapy with hydroxyurea and anagrelide, a medication that inhibits the maturation of platelets, may also be used in conjunction with phlebotomy and antiplatelet agents. PV should be considered in the differential diagnosis of stroke in multiple territories. It is imperative to pay close attention to routine blood investigation, which in this case turned out to be anything but routine.

Funding
None.

Conflict of interest
None declared.

Acknowledgments
The authors wish to thank their friends and family for their support.

References
1 Spivak JL. Polycythemia vera. Curr Treat Options Oncol 2018;19(2):12